



AdisInsight Review Report H1 - 2022

PREVIEW

This report summarizes the development of drugs in the first half of 2022, highlighting significant trends in drug research, clinical trials, and commercial deals in R&D and drug safety information as seen through the AdisInsight database.

Review
Report


Research Trends

We present here the research trends year over year by comparing 2021 H1 vs 2022 H1. Users can identify how many new profiles were created during these time frames and understand what the top 10 indications with new development were. The charts illustrate the indications of interest.


As the world continues to navigate a global pandemic, drug development progressed for COVID19, as well as other therapeutic areas. We have used the AdisInsight database to analyze how drug development advanced during the first half of 2022. The table below includes new profile counts for all indications, and compares the activity this year to what developed during the same time period in 2021.

The table below shows the H1 changes in Research Trends as indicated by New Profiles created on AdisInsight:

| Year | New Profiles H1 | % change |
|------|-----------------|----------|
| 2022 | 2319 | -17.88% |
| 2021 | 2824 | |



Top 10 indications with new products in 2021 - H1



Trial activity and success rates

Using AdisInsight, users can pinpoint trials within H1 2022 and determine success based upon whether or not they met their endpoints.

H1 Trials - 2022

| | |
|-----------------------------------|-----|
| Trials that met endpoint | 339 |
| Trials that did not meet endpoint | 149 |

H1 Trials - 2021

| | |
|-----------------------------------|-----|
| Trials that met endpoint | 456 |
| Trials that did not meet endpoint | 204 |

Safety Reports: Adverse Events H1 2022

The most often reported adverse events across all drugs in H1 were:

| Rolled-up adverse event | Number of Profiles |
|---|--------------------|
| Drug response related complications | 3442 |
| Pathological conditions, signs and symptoms | 2769 |
| Neurological disorders | 2122 |
| Cardiovascular disorders | 2050 |
| Haematological disorders | 1831 |
| Skin and connective tissue diseases | 1700 |
| Immunological disorders | 1618 |
| Digestive system disorders | 1365 |
| Signs symptoms and ill-defined conditions | 1272 |
| Infections | 1239 |

Safety Reports: Adverse Events H1 2021

The most often reported adverse events across all drugs in H1 of 2021 were:

| Rolled-up adverse event | Number of Profiles |
|---|--------------------|
| Pathological conditions, signs and symptoms | 2744 |
| Neurological disorders | 2174 |
| Drug response related complications | 2081 |
| Cardiovascular disorders | 2066 |
| Haematological disorders | 1919 |
| Skin and connective tissue diseases | 1658 |
| Immunological disorders | 1620 |
| Signs symptoms and ill-defined conditions | 1493 |
| Digestive system disorders | 1488 |
| Infections | 1427 |

Key Organization deals in H1 2022

*These acquisitions were completed in H1 and represent a significant deal value.

| Selected Company Name and Role | Headline | Deal Type | Deal Value (\$USm) |
|--|---|-------------|--------------------|
| Evotec SE(Acquiring company), Rigenrand(Acquired company) | Evotec SE/Rigenrand: Acquisition | Acquisition | 24.16 |
| CureVac(Acquiring company), Frame Therapeutics(Acquired company) | CureVac/Frame Therapeutics: Acquisition | Acquisition | 33.8 |
| Alpha-5 Integrin(Acquired company), Pasithea Therapeutics(Acquiring company) | Alpha-5 Integrin/Pasithea Therapeutics: Acquisition | Acquisition | 3.75 |
| Abound Bio(Acquired company), Galapagos NV(Acquiring company) | Abound Bio/Galapagos NV: Acquisition | Acquisition | 14 |
| CellPoint Bio(Acquired company), Galapagos NV(Acquiring company) | CellPoint Bio/Galapagos NV: Acquisition | Acquisition | 236 |
| Cancer Prevention Pharmaceuticals(Acquired company), Panbela Therapeutics(Acquiring company) | Cancer Prevention Pharmaceuticals/Panbela Therapeutics: Acquisition | Acquisition | 60 |
| Pfizer(Acquiring company), ReViral(Acquired company) | Pfizer/ReViral: Acquisition | Acquisition | 525 |
| Acacia Pharma(Acquired company), Eagle Pharmaceuticals(Acquiring company) | Acacia Pharma/Eagle Pharmaceuticals: Acquisition | Acquisition | 99.37 |
| Checkmate Pharmaceuticals(Acquired company), Regeneron Pharmaceuticals(Acquiring company) | Checkmate Pharmaceuticals/Regeneron Pharmaceuticals: Acquisition | Acquisition | 250 |
| Antares Pharma(Acquiring company), Halozyme Therapeutics(Acquiring company) | Antares Pharma/Halozyme Therapeutics: Acquisition | Acquisition | 960 |
| ModeX Therapeutics Inc(Acquired company), OPKO Health(Acquiring company) | ModeX Therapeutics Inc/OPKO Health: Acquisition | Acquisition | 300 |